Trial Review

Please note the ANZCTR will be unattended from Friday 20 December 2024 for the holidays. The Registry will re-open on Tuesday 7 January 2025. Submissions and updates will not be processed during that time.

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT00765674




Registration number
NCT00765674
Ethics application status
Date submitted
2/10/2008
Date registered
3/10/2008
Date last updated
9/05/2011

Titles & IDs
Public title
Efficacy and Safety of Aliskiren/Amlodipine/Hydrochlorothiazide in Patients With Moderate-severe Hypertension
Scientific title
An 8 Week, Double-blind, Randomized, Parallel Group, Active-controlled Study to Evaluate the Efficacy and Safety of the Combination of Aliskiren/Amlodipine/Hydrochlorothiazide in Patients With Moderate to Severe Hypertension
Secondary ID [1] 0 0
CSAH100A2302
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Hypertension 0 0
Condition category
Condition code
Cardiovascular 0 0 0 0
Hypertension

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Aliskiren
Treatment: Drugs - Amlodipine
Treatment: Drugs - Hydrochlorothiazide (HCTZ)
Treatment: Drugs - Placebo
Treatment: Drugs - Placebo

Experimental: Aliskiren / amlodipine - Patients received an aliskiren 150 mg tablet plus an amlodipine 5 mg capsule for 4 weeks and then were force titrated up to aliskiren 300 mg plus amlodipine 10 mg for the remaining 4 weeks of the study. During the 8 weeks, patients also received a placebo tablet and a placebo capsule. Patients took a total of 4 pills each day orally with water in the morning at approximately 8:00 am, except on the morning of a study visit when they took their study medications after all visit procedures and assessments had been completed.

Experimental: Aliskiren / hydrochlorothiazide - Patients received an aliskiren 150 mg tablet plus a hydrochlorothiazide 12.5 mg capsule for 4 weeks and then were force titrated up to aliskiren 300 mg plus hydrochlorothiazide 25 mg for the remaining 4 weeks of the study. During the 8 weeks, patients also received a placebo capsule and a placebo tablet. Patients took a total of 4 pills each day orally with water in the morning at approximately 8:00 am, except on the morning of a study visit when they took their study medications after all visit procedures and assessments had been completed.

Experimental: Amlodipine / hydrochlorothiazide - Patients received an amlodipine 5 mg capsule plus a hydrochlorothiazide 12.5 mg capsule for 4 weeks and then were force titrated up to amlodipine 10 mg plus hydrochlorothiazide 25 mg for the remaining 4 weeks of the study. During the 8 weeks, patients also received 2 placebo tablets. Patients took a total of 4 pills each day orally with water in the morning at approximately 8:00 am, except on the morning of a study visit when they took their study medications after all visit procedures and assessments had been completed.

Experimental: Aliskiren / amlodipine / hydrochlorothiazide - Patients received an aliskiren 150 mg tablet, a HCTZ 12.5 mg capsule and a placebo capsule for the first 3 days of treatment. Amlodipine 5 mg was then added for the remainder of the first 4 weeks of treatment. At the end of 4 weeks, patients were force titrated up to aliskiren / amlodipine / hydrochlorothiazide 300/10/25 mg for the remaining 4 weeks of the study. During the 8 weeks, patients also received a placebo tablet. Patients took a total of 4 pills each day orally with water in the morning at approximately 8:00 am, except on the morning of a study visit when they took their study medications after all visit procedures and assessments had been completed.


Treatment: Drugs: Aliskiren
150 and 300 mg tablets

Treatment: Drugs: Amlodipine
5 and 10 mg capsules

Treatment: Drugs: Hydrochlorothiazide (HCTZ)
12.5 and 25 mg capsules

Treatment: Drugs: Placebo
tablet

Treatment: Drugs: Placebo
capsules
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Change in Mean Sitting Systolic Blood Pressure (msSBP) From Baseline to End of Study (Week 8)
Timepoint [1] 0 0
Baseline to end of study (Week 8)
Secondary outcome [1] 0 0
Change in Mean Sitting Diastolic Blood Pressure (msDBP) From Baseline to End of Study (Week 8)
Timepoint [1] 0 0
Baseline to end of study (Week 8)
Secondary outcome [2] 0 0
Percentage of Patients Achieving Blood Pressure Control at the End of the Study (Week 8)
Timepoint [2] 0 0
End of study (Week 8)
Secondary outcome [3] 0 0
Change in Mean 24-hour Ambulatory Systolic and Diastolic Blood Pressure From Baseline to End of Study (Week 8)
Timepoint [3] 0 0
Baseline to end of study (Week 8)

Eligibility
Key inclusion criteria
* Male or female
* 18 years of age or older
* msDBP and msSBP requirements:

* 3A:

* Diagnosis of moderate to severe hypertension (msSBP = 160 mmHg and < 200 mmHg, and/or msDBP = 100 mmHg and < 120 mmHg) at Visits 4, 5 or 6 (Qualifying BP visit)
* In addition, at the visit immediately prior to the above qualifying visit, patients were also to have msSBP = 145 mmHg and < 200 mmHg and msDBP = 95 mmHg and < 120 mmHg) at Visits 3, 5 or 5.
* Patients had to meet the above two sets of requirements at subsequent adjacent visits, i.e. either Visits 3 and 4, Visits 4 and 5, or Visits 5 and 6.
* OR
* 3B:

* msSBP = 180 mmHg and < 200 mmHg with msDBP = 95 mmHg and < 120 mmHg, or msDBP = 110 mmHg and < 120 mmHg with msSBP = 150 mmHg and < 200 mmHg after at least one week of treatment with placebo (Visit 3 and on).
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Continued use of anti-hypertensive medicines or use of 4 or more hypertensive medicines at study start
* Patients with an msSBP = 200 mmHg or msDBP = 120 mmHg at any time during the placebo run-in period were to be discontinued from the study.
* Extremely elevated (defined) blood pressure at any point during the study
* Pregnant or lactating women
* Pre-menopausal women not taking accepted form of birth control
* History or evidence of secondary form of hypertension
* History of cardiovascular conditions

Other protocol-defined inclusion/exclusion criteria applied to the study.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s

The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
1/09/2008
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
1/08/2009
Sample size
Target
Accrual to date
Final
1191
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Investigative Site - Sydney
Recruitment postcode(s) [1] 0 0
- Sydney
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Colorado
Country [2] 0 0
Canada
State/province [2] 0 0
Ottawa
Country [3] 0 0
Denmark
State/province [3] 0 0
Copenhagen
Country [4] 0 0
Germany
State/province [4] 0 0
Berlin
Country [5] 0 0
Israel
State/province [5] 0 0
Jerusalem
Country [6] 0 0
Italy
State/province [6] 0 0
Rome
Country [7] 0 0
Latvia
State/province [7] 0 0
Riga
Country [8] 0 0
Lithuania
State/province [8] 0 0
Vilnius
Country [9] 0 0
Romania
State/province [9] 0 0
Bucharest
Country [10] 0 0
Sweden
State/province [10] 0 0
Stockholm
Country [11] 0 0
Turkey
State/province [11] 0 0
Ankara

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Novartis
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

No information has been provided regarding IPD availability


What supporting documents are/will be available?

No Supporting Document Provided



Results publications and other study-related documents

No documents have been uploaded by study researchers.

Results are available at https://clinicaltrials.gov/study/NCT00765674